NEW YORK (GenomeWeb News) – Sigma-Aldrich today said that its BioReliance business has signed an agreement to acquire colonies and cell lines for toxicology testing from Agilent Technologies.

The deal covers colonies required for Agilent's Big Blue transgenic rodent mutation assay, which are in vivo genetic toxicology assays that measure mutation frequency in tissue. BioReliance will now own the Big Blue mutation models and will be the exclusive supplier of testing services based on the model.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.